4.8 Article

Structural analysis of human KDM5B guides histone demethylase inhibitor development

期刊

NATURE CHEMICAL BIOLOGY
卷 12, 期 7, 页码 539-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.2087

关键词

-

资金

  1. Arthritis Research UK [20522]
  2. NIHR Oxford Biomedical Research Unit
  3. Sarcoma UK
  4. Bone Cancer Research Trust
  5. Rosetrees Trust
  6. Cancer Research UK [C8717/A18245, 300/A13058]
  7. CRUK Oxford Development Fund
  8. AbbVie
  9. Bayer Pharma AG
  10. Boehringer Ingelheim
  11. Canada Foundation for Innovation
  12. Genome Canada
  13. GlaxoSmithKline
  14. Janssen
  15. Lilly Canada
  16. Merck Co.
  17. Novartis Research Foundation
  18. Ontario Ministry of Economic Development and Innovation
  19. Pfizer
  20. Sao Paulo Research Foundation-FAPESP
  21. Takeda
  22. Wellcome Trust [092809/Z/10/Z]
  23. MRC [G0500905, G9400953, G1000807] Funding Source: UKRI
  24. Cancer Research UK [18245, 13058, 20776] Funding Source: researchfish
  25. Engineering and Physical Sciences Research Council [1100667] Funding Source: researchfish
  26. Medical Research Council [1382296, G0500905, G1000807, G9400953] Funding Source: researchfish
  27. Rosetrees Trust [M289-F1, M289, M271-F1] Funding Source: researchfish
  28. Versus Arthritis [20522] Funding Source: researchfish

向作者/读者索取更多资源

Members of the KDM5 (also known as JARID1) family are 2-oxoglutarate- and Fee.-dependent oxygenases that act as histone H3K4 demethylases, thereby regulating cell proliferation and stem cell self-renewal and differentiation. Here we report crystal structures of the catalytic core of the human KDM5B enzyme in complex with three inhibitor chemotypes. These scaffolds exploit several aspects of the KDM5 active site, and their selectivity profiles reflect their hybrid features with respect to the KDM4 and KDM6 families. Whereas GSK-J1, a previously identified KDM6 inhibitor, showed about sevenfold less inhibitory activity toward KDM5B than toward KDM6 proteins, KDM5-C49 displayed 25-100-fold selectivity between KDM5B and KDM6B. The cell-permeable derivative KDM5-C70 had an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K 4me3 levels. The selective inhibitor GSK 467 exploited unique binding modes, but it lacked cellular potency in the myeloma system. Taken together, these structural leads deliver multiple starting points for further rational and selective inhibitor design.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据